HUP0203136A2 - Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0203136A2 HUP0203136A2 HU0203136A HUP0203136A HUP0203136A2 HU P0203136 A2 HUP0203136 A2 HU P0203136A2 HU 0203136 A HU0203136 A HU 0203136A HU P0203136 A HUP0203136 A HU P0203136A HU P0203136 A2 HUP0203136 A2 HU P0203136A2
- Authority
- HU
- Hungary
- Prior art keywords
- atom
- alkyl
- group
- hydrogen
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 150000004885 piperazines Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 1
- 101800003906 Substance P Proteins 0.000 abstract 1
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910052799 carbon Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
A találmány (I) általános képletű piperazinszármazékokra - amelynekképletében R halogénatom vagy alkilcsoport; R1 hidrogénatom vagyalkilcsoport; R2 hidrogénatom, alkil-, alkenil- vagycikloalkilcsoport; vagy R1 és R2 a nitrogén- és szénatommal együtt egyöt- vagy hattagú heterociklusos csoportot képez; R3 trifluor-metil-,alkil-, alkoxi-, trifluor-metoxi-csoport vagy halogénatom; R4hidrogénatom, -(CH2)qR7 vagy -(CH2)rCO(CH2)pR7 csoport; R5hidrogénatom, alkil- vagy -COR6 csoport; R10 hidrogénatom,alkilcsoport; vagy R10 és R2 együtt cikloalkilcsoportot képez; mértéke 0, 1, 2 vagy 3; n értéke 0, 1, 2 vagy 3; azzal a megkötéssel,hogy ha R1 és R2 azzal a nitrogénatommal és szénatommal együtt,amelyhez kapcsolódik, egy öt- vagy hattagú heterociklusos csoportotképez, i) m értéke 1 vagy 2; ii) ha m értéke 1, akkor R jelentésefluoratomtól eltérő, és iii) ha m értéke 2, akkor a két Rszubsztituens legalább egyikének a jelentése fluoratomtól eltérő, valamint gyógyászatilag elfogadható sóikra és szolvátjaikravonatkozik. A találmány kiterjed a találmány szerinti vegyületekelőállítási eljárásaira, a vegyületeket tartalmazógyógyszerkészítményekre és a vegyületek gyógyászati készítményekelőállítására vonatkozó felhasználására is. A találmány szerintivegyületek a tachykininek, köztük a P anyag (substance P) és másneurokininek antagonistái. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9923748.9A GB9923748D0 (en) | 1999-10-07 | 1999-10-07 | Chemical compounds |
PCT/EP2000/009722 WO2001025219A2 (en) | 1999-10-07 | 2000-10-05 | Piperazine compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203136A2 true HUP0203136A2 (hu) | 2003-02-28 |
HUP0203136A3 HUP0203136A3 (en) | 2003-03-28 |
Family
ID=10862304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203136A HUP0203136A3 (en) | 1999-10-07 | 2000-10-05 | Piperazine compounds, process for their preparation, pharmaceutical compositions containing them and their use |
Country Status (33)
Country | Link |
---|---|
US (6) | US6951861B1 (hu) |
EP (3) | EP1454901B1 (hu) |
JP (1) | JP4776844B2 (hu) |
KR (2) | KR100857671B1 (hu) |
CN (1) | CN100413850C (hu) |
AR (2) | AR025975A1 (hu) |
AT (3) | ATE407125T1 (hu) |
AU (1) | AU768780B2 (hu) |
BR (1) | BR0014541A (hu) |
CA (1) | CA2386515C (hu) |
CO (1) | CO5251467A1 (hu) |
CY (2) | CY1110172T1 (hu) |
CZ (1) | CZ302340B6 (hu) |
DE (3) | DE60042501D1 (hu) |
DK (3) | DK1454901T3 (hu) |
ES (3) | ES2329130T3 (hu) |
GB (1) | GB9923748D0 (hu) |
HK (3) | HK1052506B (hu) |
HU (1) | HUP0203136A3 (hu) |
IL (2) | IL148964A0 (hu) |
MX (1) | MXPA02003515A (hu) |
MY (1) | MY130907A (hu) |
NO (1) | NO323776B1 (hu) |
NZ (2) | NZ518144A (hu) |
PE (1) | PE20010741A1 (hu) |
PL (1) | PL201191B1 (hu) |
PT (3) | PT1454901E (hu) |
SI (3) | SI1460066T1 (hu) |
TN (1) | TNSN00194A1 (hu) |
TR (1) | TR200200936T2 (hu) |
TW (1) | TWI225485B (hu) |
WO (1) | WO2001025219A2 (hu) |
ZA (1) | ZA200202589B (hu) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1152761B1 (en) * | 1999-02-18 | 2009-06-24 | Novasearch AG | Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0108595D0 (en) * | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
GB0108594D0 (en) * | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
GB0119797D0 (en) * | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
US7482365B2 (en) | 2002-02-08 | 2009-01-27 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases |
DE10209145A1 (de) * | 2002-03-01 | 2003-09-04 | Bayer Cropscience Ag | Halogenbenzole |
EP1556054A4 (en) * | 2002-05-29 | 2007-09-05 | Univ California | ANTAGONIZING NK1 RECEPTORS RESTRICT DRUG ABUSE |
JP4079727B2 (ja) | 2002-09-06 | 2008-04-23 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法 |
WO2004067093A2 (en) * | 2003-01-27 | 2004-08-12 | Glaxo Group Limited | Nk1 receptor antagonists for the treatment of functional dyspepsia |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
WO2004110996A1 (en) * | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
US20060148783A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20060148781A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder in a non-human mammal |
US20070142367A1 (en) * | 2003-11-10 | 2007-06-21 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20060148782A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both |
US20050113365A1 (en) * | 2003-11-10 | 2005-05-26 | Sir Isaac Newton Enterprises Llc | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
CA2547467A1 (en) * | 2003-11-28 | 2005-06-09 | Tanabe Seiyaku Co., Ltd. | Piperidine compound and method for producing same |
WO2005068427A1 (ja) * | 2004-01-14 | 2005-07-28 | Takeda Pharmaceutical Company Limited | カルボキサミド誘導体およびその用途 |
US7855218B2 (en) * | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
JP4904945B2 (ja) | 2006-06-30 | 2012-03-28 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体の製造方法 |
GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
JP5510040B2 (ja) * | 2010-04-28 | 2014-06-04 | セントラル硝子株式会社 | 光学活性(r)−1−(4−フルオロフェニル)エチルアミンを得る光学分割 |
WO2012175434A1 (en) | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Pharmaceutical formulations comprising vestipitant |
EP2729147B1 (en) | 2011-07-04 | 2017-09-06 | IRBM - Science Park S.p.A. | Nk-1 receptor antagonists for treating corneal neovascularisation |
SG11201404880UA (en) * | 2012-02-22 | 2014-09-26 | Leo Pharma As | Novel neurokinin 1 receptor antagonist compounds |
WO2015024203A1 (en) | 2013-08-20 | 2015-02-26 | Leo Pharma A/S | Novel neurokinin 1 receptor antagonist compounds ii |
EP3237379B1 (en) | 2014-12-23 | 2022-04-06 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
EP3388423B1 (en) | 2015-12-07 | 2020-05-27 | Kissei Pharmaceutical Co., Ltd. | Nk1 receptor antagonist |
CN110730662A (zh) | 2017-04-10 | 2020-01-24 | 才思治疗公司 | 用于治疗共核蛋白病的nk1-拮抗剂组合和方法 |
CN111032158A (zh) | 2017-06-30 | 2020-04-17 | 才思治疗公司 | 用于治疗抑郁的nk-1拮抗剂组合物和方法 |
CA3076823A1 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4379152A (en) | 1974-05-09 | 1983-04-05 | Toyama Chemical Co., Ltd. | Cephalosporins |
US4087424A (en) | 1974-05-09 | 1978-05-02 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4327097A (en) | 1974-05-09 | 1982-04-27 | Toyama Chemical Co., Ltd. | Novel penicillins |
US4110327A (en) | 1974-05-09 | 1978-08-29 | Toyama Chemical Co., Ltd. | 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives |
US4219554A (en) | 1974-05-09 | 1980-08-26 | Toyama Chemical Company, Limited | Novel penicillins and cephalosporins and process for producing same |
US4410522A (en) | 1974-05-09 | 1983-10-18 | Toyama Chemical Co., Ltd. | Cephalosporins |
IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
US4112090A (en) | 1974-05-09 | 1978-09-05 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
NO154582C (no) * | 1978-10-20 | 1986-11-05 | Ferrosan Ab | Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider. |
JPS57118587A (en) | 1981-11-26 | 1982-07-23 | Toyama Chem Co Ltd | Novel penicillin |
US5028610A (en) | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
GB8709666D0 (en) | 1987-04-23 | 1987-05-28 | Beecham Group Plc | Compounds |
GB8713061D0 (en) | 1987-06-04 | 1987-07-08 | Beecham Group Plc | Compounds |
US5109014A (en) | 1990-12-10 | 1992-04-28 | Jacobson Richard M | N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides |
SE9100860D0 (sv) | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
EP0533280B2 (en) | 1991-09-20 | 2004-12-01 | Glaxo Group Limited | Novel medical use for tachykinin antagonists |
EP0545478A1 (en) | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclic compounds as tachykinin antagonists |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
WO1996003378A1 (fr) | 1994-07-26 | 1996-02-08 | Sankyo Company, Limited | Derives d'amide n-phenyle et d'uree |
US5696123A (en) | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
DE19520499C2 (de) | 1994-09-17 | 2003-06-18 | Boehringer Ingelheim Kg | Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung |
US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
DE69534213T2 (de) | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
US5576317A (en) | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
EP0799202A1 (de) | 1994-12-23 | 1997-10-08 | Dr. Karl Thomae GmbH | Piperazinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US5700801A (en) | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
DE19608665A1 (de) | 1996-03-06 | 1997-09-11 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
US6057323A (en) | 1996-03-08 | 2000-05-02 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU706495B2 (en) * | 1996-04-03 | 1999-06-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036888A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0904080A4 (en) | 1996-04-03 | 2001-08-01 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
AU3359697A (en) | 1996-07-08 | 1998-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Bone resorption inhibitors |
EP0912174B1 (en) * | 1996-07-17 | 2004-04-28 | MERCK & CO., INC. | Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
US5929077A (en) | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
US6114315A (en) | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
EP0942730A1 (en) | 1996-12-02 | 1999-09-22 | MERCK SHARP & DOHME LTD. | Use of nk-1 receptor antagonists for treating bipolar disorders |
US5977104A (en) | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
AU741725B2 (en) | 1997-08-27 | 2001-12-06 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
ATE267168T1 (de) | 1997-11-24 | 2004-06-15 | Merck & Co Inc | Beta-alanin-derivate als zell-adhäsions- inhibitoren |
TR200101649T2 (tr) * | 1998-12-14 | 2001-10-22 | Fujisawa Pharmaceutical Co., Ltd. | Piperazin türevleri. |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
WO2001030348A1 (en) * | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
US20030022891A1 (en) | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
-
1999
- 1999-10-07 GB GBGB9923748.9A patent/GB9923748D0/en not_active Ceased
-
2000
- 2000-10-05 EP EP04076650A patent/EP1454901B1/en not_active Expired - Lifetime
- 2000-10-05 ES ES04076632T patent/ES2329130T3/es not_active Expired - Lifetime
- 2000-10-05 EP EP04076632A patent/EP1460066B1/en not_active Expired - Lifetime
- 2000-10-05 HU HU0203136A patent/HUP0203136A3/hu unknown
- 2000-10-05 CO CO00075822A patent/CO5251467A1/es active IP Right Grant
- 2000-10-05 JP JP2001528165A patent/JP4776844B2/ja not_active Expired - Fee Related
- 2000-10-05 CN CNB008158606A patent/CN100413850C/zh not_active Expired - Fee Related
- 2000-10-05 DE DE60042501T patent/DE60042501D1/de not_active Expired - Lifetime
- 2000-10-05 PT PT04076650T patent/PT1454901E/pt unknown
- 2000-10-05 AU AU79139/00A patent/AU768780B2/en not_active Ceased
- 2000-10-05 AT AT04076650T patent/ATE407125T1/de active
- 2000-10-05 TR TR2002/00936T patent/TR200200936T2/xx unknown
- 2000-10-05 AT AT04076632T patent/ATE435215T1/de active
- 2000-10-05 DK DK04076650T patent/DK1454901T3/da active
- 2000-10-05 DK DK00969414T patent/DK1218359T3/da active
- 2000-10-05 PL PL356261A patent/PL201191B1/pl unknown
- 2000-10-05 CA CA2386515A patent/CA2386515C/en not_active Expired - Lifetime
- 2000-10-05 PT PT00969414T patent/PT1218359E/pt unknown
- 2000-10-05 WO PCT/EP2000/009722 patent/WO2001025219A2/en active IP Right Grant
- 2000-10-05 BR BR0014541-6A patent/BR0014541A/pt not_active Application Discontinuation
- 2000-10-05 SI SI200031037T patent/SI1460066T1/sl unknown
- 2000-10-05 AT AT00969414T patent/ATE270664T1/de active
- 2000-10-05 EP EP00969414A patent/EP1218359B1/en not_active Expired - Lifetime
- 2000-10-05 KR KR1020077026231A patent/KR100857671B1/ko not_active IP Right Cessation
- 2000-10-05 CZ CZ20021166A patent/CZ302340B6/cs not_active IP Right Cessation
- 2000-10-05 SI SI200030492T patent/SI1218359T1/xx unknown
- 2000-10-05 MX MXPA02003515A patent/MXPA02003515A/es active IP Right Grant
- 2000-10-05 DE DE60040176T patent/DE60040176D1/de not_active Expired - Lifetime
- 2000-10-05 NZ NZ518144A patent/NZ518144A/xx not_active IP Right Cessation
- 2000-10-05 KR KR1020027004438A patent/KR100817373B1/ko not_active IP Right Cessation
- 2000-10-05 SI SI200031010T patent/SI1454901T1/sl unknown
- 2000-10-05 IL IL14896400A patent/IL148964A0/xx active IP Right Grant
- 2000-10-05 NZ NZ531127A patent/NZ531127A/en not_active IP Right Cessation
- 2000-10-05 PT PT04076632T patent/PT1460066E/pt unknown
- 2000-10-05 ES ES04076650T patent/ES2312917T3/es not_active Expired - Lifetime
- 2000-10-05 MY MYPI20004668A patent/MY130907A/en unknown
- 2000-10-05 DK DK04076632T patent/DK1460066T3/da active
- 2000-10-05 US US10/089,964 patent/US6951861B1/en not_active Expired - Lifetime
- 2000-10-05 ES ES00969414T patent/ES2222927T3/es not_active Expired - Lifetime
- 2000-10-05 DE DE60012031T patent/DE60012031T2/de not_active Expired - Lifetime
- 2000-10-06 TN TNTNSN00194A patent/TNSN00194A1/en unknown
- 2000-10-06 AR ARP000105284A patent/AR025975A1/es not_active Application Discontinuation
- 2000-10-06 PE PE2000001068A patent/PE20010741A1/es not_active Application Discontinuation
- 2000-10-07 TW TW089121014A patent/TWI225485B/zh not_active IP Right Cessation
-
2002
- 2002-04-01 IL IL148964A patent/IL148964A/en not_active IP Right Cessation
- 2002-04-03 ZA ZA200202589A patent/ZA200202589B/en unknown
- 2002-04-05 NO NO20021637A patent/NO323776B1/no not_active IP Right Cessation
- 2002-07-03 US US10/190,170 patent/US6642240B2/en not_active Ceased
-
2003
- 2003-07-03 HK HK03104740.2A patent/HK1052506B/zh not_active IP Right Cessation
- 2003-08-08 US US10/637,825 patent/US7071196B2/en not_active Expired - Fee Related
-
2004
- 2004-05-04 US US10/838,838 patent/US20040209893A1/en not_active Abandoned
- 2004-11-06 HK HK04108748A patent/HK1065798A1/xx not_active IP Right Cessation
- 2004-12-01 HK HK04109454.6A patent/HK1066537A1/xx not_active IP Right Cessation
-
2006
- 2006-01-18 US US11/334,267 patent/US7345041B2/en not_active Expired - Fee Related
-
2007
- 2007-12-13 US US11/955,847 patent/US7625904B2/en not_active Expired - Fee Related
-
2008
- 2008-11-27 CY CY20081101376T patent/CY1110172T1/el unknown
-
2009
- 2009-09-18 CY CY20091100969T patent/CY1110104T1/el unknown
-
2010
- 2010-07-15 AR ARP100102567A patent/AR077414A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203136A2 (hu) | Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0200021A2 (hu) | 4-(Heterociklikus szulfonamido)-5-metoxi-6-(2-metoxi-fenoxi)-2-fenil- vagy -piridil-pirimidinek, mint endothelin receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0301311A2 (hu) | N-oxidok mint 4-fenil-piridin-származékok előgyógyszerei, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0000562A2 (hu) | Kondenzált pirazolszármazékok, eljárás előállításukra, alkalmazásuk és az azokat tartalmazó gyógyszerkészítmények | |
HUP0300565A2 (hu) | PDE 5 inhibitor hatású 8-kinolin-xantin- és 8-izo-kinolin-xantin-származékok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0004150A2 (hu) | Tirozin kináz receptor antagonista hatású indazolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0400558A2 (hu) | Helyettesített benzolszármazékok, illetve sóik és ezeket tartalmazó gyógyszerkészítmények | |
HUP9902471A2 (hu) | Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0401876A2 (hu) | Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0102471A2 (hu) | 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények | |
HUP0002112A2 (hu) | Helyettesített 3-ciano-kinolinok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
HUP0301272A2 (hu) | 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására | |
HUP0302487A2 (hu) | Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
HUP0004564A2 (hu) | Gasztrokinetikus hatású 3- vagy 4-szubsztituált 4-(aminometil)-piperidin-származékok monociklusos benzamidjai, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0402225A2 (hu) | Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0002461A2 (hu) | Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0401886A2 (hu) | Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0301811A2 (hu) | Hipolipidémiás és hipokoleszterinémiás hatású szubsztituált pirrolszármazékok, azokat tartalmazó gyógyszerkészítmények, eljárás elżállításukra, köztitermékek és alkalmazásuk | |
MY132062A (en) | Apolipoprotein-b synthesis inhibitors | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
HUP0200121A2 (hu) | Kalcilitikus vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0201315A2 (hu) | 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények | |
HUP0401018A2 (hu) | 2H-1-benzopirán-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények | |
HUP0102931A2 (hu) | Új N-(triazolil-metil)-piperazin-származékok mint neurokininreceptor-antagonisták |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: GLAXO GROUP LIMITED, GB Free format text: FORMER OWNER(S): GLAXO GROUP LIMITED, GB |
|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |